EP1667669A2 - Entzündliche darmerkrankungen - Google Patents
Entzündliche darmerkrankungenInfo
- Publication number
- EP1667669A2 EP1667669A2 EP04776179A EP04776179A EP1667669A2 EP 1667669 A2 EP1667669 A2 EP 1667669A2 EP 04776179 A EP04776179 A EP 04776179A EP 04776179 A EP04776179 A EP 04776179A EP 1667669 A2 EP1667669 A2 EP 1667669A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- levels
- proteins
- patient
- disease
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 78
- 208000011231 Crohn disease Diseases 0.000 claims description 181
- 108090000623 proteins and genes Proteins 0.000 claims description 82
- 102000004169 proteins and genes Human genes 0.000 claims description 82
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 81
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 48
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 29
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 29
- 102100035194 Placenta growth factor Human genes 0.000 claims description 26
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 24
- 210000001124 body fluid Anatomy 0.000 claims description 19
- 102000003810 Interleukin-18 Human genes 0.000 claims description 17
- 108090000171 Interleukin-18 Proteins 0.000 claims description 17
- 102100023701 C-C motif chemokine 18 Human genes 0.000 claims description 13
- -1 SCD23 Proteins 0.000 claims description 13
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 12
- 108010002586 Interleukin-7 Proteins 0.000 claims description 12
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 11
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 11
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 11
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 11
- 102100021592 Interleukin-7 Human genes 0.000 claims description 11
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 10
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 claims description 8
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims description 6
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims description 6
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims description 6
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 5
- 101150064015 FAS gene Proteins 0.000 claims description 5
- 101710086591 Hepatocyte growth factor-like protein Proteins 0.000 claims description 5
- 102000003815 Interleukin-11 Human genes 0.000 claims description 5
- 108090000177 Interleukin-11 Proteins 0.000 claims description 5
- 101710201137 Photosystem II manganese-stabilizing polypeptide Proteins 0.000 claims description 5
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 5
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims description 4
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims description 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 4
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004890 Interleukin-8 Human genes 0.000 claims description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 4
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000856395 Homo sapiens Cullin-9 Proteins 0.000 claims description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 101150038998 PLAUR gene Proteins 0.000 claims description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 2
- 108700012411 TNFSF10 Proteins 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims 18
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 7
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 6
- 101150062285 PGF gene Proteins 0.000 claims 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 4
- 102100025142 Beta-microseminoprotein Human genes 0.000 claims 2
- 101100441523 Homo sapiens CXCL5 gene Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 36
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 102000004127 Cytokines Human genes 0.000 description 121
- 108090000695 Cytokines Proteins 0.000 description 121
- 210000002966 serum Anatomy 0.000 description 37
- 238000012313 Kruskal-Wallis test Methods 0.000 description 22
- 108010082093 Placenta Growth Factor Proteins 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 102100032813 Hepatocyte growth factor-like protein Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000002790 cross-validation Methods 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 238000002493 microarray Methods 0.000 description 14
- 230000001419 dependent effect Effects 0.000 description 13
- 241001408449 Asca Species 0.000 description 12
- 230000009266 disease activity Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 102000019034 Chemokines Human genes 0.000 description 10
- 108010012236 Chemokines Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 206010009887 colitis Diseases 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 8
- 239000012491 analyte Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 5
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000000112 colonic effect Effects 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028124 Mucosal ulceration Diseases 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- LCHWKMAWSZDQRD-UHFFFAOYSA-N silylformonitrile Chemical compound [SiH3]C#N LCHWKMAWSZDQRD-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 241001275954 Cortinarius caperatus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108700024827 HOC1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005560 Homo sapiens CCL23 gene Proteins 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 101000991619 Homo sapiens Meprin A subunit alpha Proteins 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100030882 Meprin A subunit alpha Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 108010007389 Trefoil Factors Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 201000008267 intestinal tuberculosis Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013409 limited attention Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 102000049853 macrophage stimulating protein Human genes 0.000 description 1
- 108010053292 macrophage stimulating protein Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000031972 neutrophil apoptotic process Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 108010012038 peptide 78 Proteins 0.000 description 1
- 229940125863 peptide 78 Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000007995 vascular wound healing Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Definitions
- the invention relates in some of its aspects to diagnosis of inflammatory bowel disease. More particularly, it relates in some of its aspects to Ulcerative Colitis and Crohn's Disease.
- IBD Inflammatory bowel disease
- GI gastrointestinal
- CD Crohn's disease
- UC ulcerative colitis
- CD represents a nonspecific chronic transmural inflammatory disease that most commonly affects the distal ileum and colon but may occur in any part ofthe GI tract.
- UC is defined as a chronic, inflammatory, and ulcerative disease arising in the colonic mucosa, characterized most often by bloody diarrhea.
- the Western-Eastern discrepancy can be attributed to a difference in life styles.
- the incidence of the disease has been increasing worldwide, but its spread has been slowing down in highly affected countries.
- Racial and ethnic relations in different populations and immigration studies offer interesting data, which can reflect genetic, environmental and behavioral factors (Karlinger et al. 2000).
- the disease seems to have a characteristic racial-ethnic distribution: the Jewish population is highly susceptible everywhere, but its prevalence in that population nears that of the domestic society in which they live. In Hungary, the Roma (Gypsies) have a considerably lower prevalence than the average population. This can be attributed to a genetic or environmental influence.
- the onset of the disease occurs more often in the second or the third decade of life, but there also is another peak in the 60s.
- IBD infectious bacteria
- Yersinia Campylobacter
- Clostridium Clomidia
- herpesvirus rotavirus
- the primary measles virus Karlinger et al. 2000. None of them has been proven as a real and exclusively pathogenic factor.
- Irnmunological background has an important function in the manifestation of the disease. If an individual has a genetic susceptibility to infections, the down regulation of an inflammation in the bowel wall may not occur in a proper way and may initiate an autoimmune process.
- ulcerative colitis and Crohn's disease are heterogeneous disorders of mutifactorial etiology in which hereditary (genetic) and environmental (microbial, behavior) factors interact to produce the disease.
- IL-10 inhibits the production of proinflammatory cytokines such as IL-1, tumor necrosis factor-alpha (TNF-a), interferon-gamma (EFN-gamma) and IL-6 through inhibitory action on Thl cells and macrophages, and it is thought to be a suppressor type cytokine.
- IL-10 is elevated in serum of patients with active CD and UC, suggesting that IL-10 acts as a naturally occurring damper in the acute inflammatory process of IBD.
- M-CSF Macrophage-colony stimulating factor
- salivary M-CSF influences monocyte/macrophage proliferation, differentiation, and activation.
- Serum M- CSF levels were found to be increased in active IBD, and compared to normal intestine, in active IBD the frequency of M-CSF-expressing cells was significantly increased and their distribution markedly altered, although no increase in mucosal M-CSF mRNA levels in intestinal tissue was observed (Klebl et al. 2001). However, the changes were not specific to IBD, as there were similar findings in intestinal tuberculosis and ischaemic colitis.
- TNF-alpha and IL-6 were significantly increased in the CD group only.
- Chemokines, together with key cytokines that promote their release are elevated in mucosal tissues from patients with IBD. It is likely that these chemokines play an important role in the perpetuation of tissue destructive inflammatory processes.
- antisense ohgonucleotides (anti-ICAM), anti- cytokine antibodies (anti-TNF) or recombinant human cytokines (IL-10 or IL-11) are effective in some patients with Crohn's disease refractory to steroids (Heresbach et al. 1999). However, these data need to be confirmed and the potential side effects of these treatments must be further considered.
- Figures 1-15 provide data which were generated in identifying the biomarkers of the present invention.
- cytokine profiles of IBD patients and normal controls were able to build cytokine classifiers for most of the 11 comparisons and to correctly categorize both original and cross-validated cases with a high success rate.
- the cytokines, identified as classifiers represent biomarkers that can be used to diagnose IBD, and biomarkers that correlate with disease activity.
- the ability to diagnose IBD early, based on biomarkers, will result in timely therapeutic intervention and improved outcome.
- the ability to evaluate and predict the disease activity will enable the design of more appropriate treatments, adapted to the precise molecular mechanisms that are dysregulated in EBD.
- Anti-TNF therapy has been shown to be effective against rheumatoid arthritis and Crohn's disease (Raza 2000; Emery et al. 2001).
- the identification of additional cytokines, involved in the pathogenesis of IBD, may allow the design of combination therapies v/ith several anti-cytokine antibodies.
- Antibody microarrays were printed using a Packard Biosciences (Downers Grove, IL) BCA-II piezoelectric microarray dispenser on cyanosilane-coated glass slides divided by Teflon boundaries into sixteen 0.5 cm diameter circular subarrays. Monoclonal antibodies for 78 cytokines (see Supplementary Material for listing of antibodies and vendors) were dispensed in quadruplicate at a concentration of 0.5 mg/mL. Printed slides were blocked as described (Schweitzer et al. 2002) and stored at 4oC until use. Batches of slides were subjected to a quality control consisting of incubation with a fluorescently-labeled anti-mouse antibody, followed by washing, scanning and quantitation. Typically, the coefficient of variability (CV) of antibody deposition in printing was ⁇ 5%.
- CV coefficient of variability
- the assay was performed by a liquid-handhng robot (Biomek 2000, Beckman Instruments, Fullerton, CA), which was enclosed in an 80% humidified, HEPA- filtered, plexiglass chamber. 15 mL sample was applied to each subarray, and immunoassays with RCA signal amplification were performed as described (Schweitzer et al., 2002). Slides were scanned (GenePix, Axon Instruments Inc., Foster City, CA) at 10-mm resolution with laser setting of 100 and PMT setting of 550. Mean pixel fluorescence were quantified using the fixed circle method in GenePix Pro 3.0 (Axon instruments, Foster City, CA). The fluorescence intensity of quadruplicate microarray features was averaged for each feature and sample, and the resulting cytokine values were determined. For every slide, a set of blanks was run and the intensity values were used to correct for background signal.
- Antibody microarrays were printed using a Packard Biosciences (Downers Grove, EL) BCA-II piezoelectric microarray dispenser on cyanosilane-coated glass slides divided by Teflon boundaries into sixteen 0.5 cm diameter circular subarrays. Monoclonal antibodies for 78 cytokines were dispensed in quadruplicate at a concentration of 0.5 mg/mL. Printed slides were blocked as described (Schweitzer et al. 2002) and stored at 4°C until use. Batches of slides were subjected to a quality control consisting of incubation with a fluorescently-labeled anti-mouse antibody, followed by washing, scanning and quantitation. Typically, the coefficient of variability (CV) of antibody deposition in printing was ⁇ 5%.
- the assay was performed by a liquid-handling robot (Biomek 2000, Beckman Instruments, Fullerton, CA), which was enclosed in an 80% humidified, HEPA- filtered, plexiglass chamber. 15 ⁇ L sample was applied to each subarray, and immunoassays with RCA signal amplification were performed as described (Schweitzer et al., 2002). Slides were scanned (GenePix, Axon instruments Inc., Foster City, CA) at 10- ⁇ m resolution with laser setting of 100 and PMT setting of 550. Mean pixel fluorescence were quantified using the fixed circle method in GenePix Pro 3.0 (Axon Instruments, Foster City, CA). The fluorescence intensity of quadruplicate microarray features was averaged for each feature and sample, and the resulting cytokine values were determined. For every slide, a set of blanks was run and the intensity values were used to correct for background signal.
- Cross-validation a method for testing the robustness of a prediction model, was then carried out.
- To cross-validate a prediction model one removes and sets aside one sample, uses the remaining samples to build a prediction model based on the preselected cytokine predictors, and determines whether the new model is able to predict the one sample not used in building the new model correctly. This process is repeated for all samples one at a time, and a cumulative cross-validation rate can then be calculated.
- the final list of cytokine predictors was determined by manually entering and removing cytokines to maximize the cross-validation rate, using information obtained from the univariate analyses and cross-validations.
- the final cytokine classifier is then defined as the set of cytokine predictors that gives the highest cross-validation rate.
- the aim of our study is to find biomarkers for IBD and for disease activity.
- Serum samples from IBD patients and from age-matched normal controls were analyzed using the cytokine chip (see Materials and Methods). After QC, data from 61 IBD patients and 63 normal controls were used in statistical analyses. Univariate analysis (Kruskal-Wallis test) was carried out to detect differences in the serum cytokine levels between the groups and to identify potential predictors. Multivariate analysis (linear discriminant analysis) was then performed to determine differences between the cytokine profiles of the groups. Prediction models were built and found to be capable of predicting IBD with high success rate in both original and cross-validation cases (see below).
- CD patients (clinical remission) vs. CD patients (active disease) - to identify biomarkers that correlate with Crohn's disease activity 2. All CD patients vs. all normal controls - to identify biomarkers that can be used to diagnose CD 3. CD patients (active disease) vs. all normal controls - to identify biomarkers that can be used to diagnose active CD 4. All UC patients vs. all CD patients - to identify biomarkers that can be used to differentiate UC from CD 5. All UC patients vs.
- Figure 1 shows the serum PLGF (placenta growth factor) levels in CD patients in clinical remission and in CD patients with active disease.
- the mean intensity of PLGF in the remission group (556+233) was higher than the active group (336 ⁇ 250).
- the Kruskal-Wallis test identified PLGF as the marker with highest statistical significance in Comparison 1 (CD remission vs. CD active) (Table 1), suggesting that PLGF is a potential class predictor.
- Table 1 shows that PLGF is a potential class predictor.
- Table 1 the ranges of PLGF levels for the two groups overlap significantly ( Figure 1).
- serum PLGF level by itself is not a good predictor of Crohn's disease activity.
- LDA linear discriminant analysis
- PLGF placenta growth factor
- placenta growth factor
- NEGF vascular endothelial growth factor
- NEGF nerve growth factor receptor
- monocytes express the VEGF receptor Flt-1, and this receptor specifically binds also the NEGF homolog PLGF. Both NEGF and PLGF stimulate tissue factor production and chemotaxis in monocytes at equivalent doses.
- Flt-1 is a functional receptor for VEGF and PLGF in monocytes and endothelial cells and a mediator of monocyte recruitment and procoagulant activity (Clauss et al. 1996). Blood monocytes are recruited to the inflammatory bowel disease mucosa, and the phenotype of the recently-arrived monocytes indicates their susceptibility to stimulation by lipopolysaccharide, suggesting a mechanism for the continuing inflammation in the bacterial product-rich milieu of IBD (Grimm et al. 1995). If used individually, PLGF will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 10- cytokine classifier, the correct classification rate is considerably improved.
- PLGF was also identified as a classifier cytokine in Comparison 8, all CD patients vs. normal controls ( ⁇ 9 years of age). [49] For Comparison 2, all CD patients vs. all normal controls, we were able to build a 22-cytokine classifier that correctly categorized 96.2% of original grouped cases and 93.3% of cross-validated grouped cases. The number of cytokines used in this classifier is within the range of maximum confidence level, as shown in Figure 12. This 22-cytokine classifier was almost equally successful in correctly categorizing individuals from both groups (Table 13-2).
- GM-CSF was also one of the cytokines in the classifier. If used individually, G-CSF or other cytokines will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 22-cytokine classifier, the correct classification rate is considerably improved. G-CSF was also identified as a classifier cytokine in Comparisons 4 (all UC patients vs. all CD patients), 5 (all UC patients vs. all normal controls ) and 6 (CD patients ⁇ 9 years of age vs. normal controls ⁇ 9 years of age).
- MIG MIG, ENA-78
- mRNA levels encoding MIG and other chemokines were significantly increased in chronically inflamed colons when compared with wild type mice.
- reversal of colitis by anti-IL-12 mAb was accompanied by the inhibition in the expression of MIG and other chemokines (Scheerens et al. 2001).
- ENA-78 and other chemokines are highly expressed in the intestinal mucosa in areas of active Crohn's disease and ulcerative colitis (MacDermott 1999). Chemokines, including ENA-78, have been proposed to play a central role of in the immunopathogenesis of IBD (MacDermott et al. 1998). If used individually, MIG and ENA-78 will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 12-cytokine classifier, the correct classification rate is considerably improved. ENA-78 was also identified as a classifier cytokine in Comparisons 2 (all CD patients vs. all normal controls) and 9 (all CD patients vs.
- FIG. 13 A Venn diagram representing the overlap of the best cytokine classifiers from Comparisons 1, 2 and 3 is shown in Figure 13. Although there are no cytokines common for all 3 classifiers, there are 2 common cytokines (BDNF and sCD23) between the classifiers from Comparisons 1 and 2, one cytokine (1-309) is shared between the classifiers from Comparisons 1 and 3, and 4 cytokines (ENA-78, MSP, NT3 and PARC) are common between the classifiers from Comparisons 2 and 3.
- BDNF and sCD23 common cytokines
- EDA-78, MSP, NT3 and PARC 4 cytokines
- CD45RO+CD8+ T cells Fas mediated apoptosis of CD45RO+CD8+ T cells was reported to be higher in UC patients than the controls, while the number of apoptotic CD45RO+CD4+ T cells from UC mucosa was not (Suzuki et al. 2000).
- CD45RO+CD4+ T cells are less sensitive to apoptotic signals mediated by Fas, which may contribute to the pathogenesis of UC. If used individually, FAS or other cytokines will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 6-cytokine classifier, the correct classification rate is considerably improved. [53] For Comparison 5, all UC patients vs.
- HCC-4 Three of them (HCC-4, IL-7, G-CSF) were identified also by Kruskal-Wallis test to be significantly different between the 2 groups (Table 5). It has been shown that the serum IL-7 concentration was significantly increased in UC patients (Watanabe et al. 1997). IL-7 mRNA expression is increased in the thymus tissues from patients but decreased in the colonic mucosa. Since IL-7 is a crucial cytokine for proliferation and differentiation of T cells in the thymus, these results indicate that TL-7 may contribute to the disturbance of immune regulatory T cells in ulcerative colitis.
- IL-7 transgenic mice develop acute and chronic colitis with histopathological similarity to ulcerative colitis in humans (Watanabe et al. 1999).
- IL-7 stimulates the proliferation of inactivated mucosal lymphocytes but eliminates activated lymphocytes in the inflamed mucosa of human ulcerative colitis.
- These findings suggest that chronic inflammation in the colonic mucosa is mediated by dysregulation of epithelial cell-derived IL-7 system. If used individually, IL-7 or other cytokines will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 7-cytokine classifier, the correct classification rate is considerably improved.
- FIG. 14 A Venn diagram representing the overlap of the best cytokine classifiers from Comparisons 4 and 5 is shown in Figure 14. There is 1 common cytokine (G- CSF) between the classifiers from Comparisons 4 and 5. The relevance of G-CSF to IBD was discussed above.
- G- CSF common cytokine
- EGF epidermal growth factor family
- TGF alpha transforming growth factor alpha
- EGF beta transforming growth factor beta
- IGF insulinlike growth factors
- FGF fibroblast growth factors
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- Intestinal barrier dysfunction concomitant with high levels of reactive oxygen metabolites (ROM) in the inflamed mucosa have been observed in IBD (Banan et al. 2000b).
- the cytoskeletal network has been suggested to be involved in the regulation of barrier function.
- Growth factors epidermal growth factor (EGF) and transforming growth factor alpha (TGF- ' alpha)
- EGF epidermal growth factor
- TGF- ' alpha transforming growth factor alpha
- Caco-2 monolayers were preincubated with EGF, TGF-alpha, or vehicle before incubation with ROM (H(2)O(2) or HOC1).
- Growth factor pretreatment decreased actin oxidation and enhanced the stable F-actin, while in concert prevented actin disruption and restored normal barrier function of monolayers exposed to ROM.
- Cytochalasin-D an inhibitor of actin assembly, not only caused actin disassembly and barrier dysfunction but also abolished the protective action of EGF and TGF-alpha.
- an actin stabilising agent, phalloidin mimicked the protective actions ofthe EGF and TGF-alpha (Banan et al. 2000b).
- Organization and stability ofthe microtubule cytoskeleton appears to be critical to both oxidant-induced mucosal barrier dysfunction and protection of intestinal barrier mediated by growth factors. Therefore, microtubules may be useful targets for development of drugs for the treatment of IBD (Banan et al. 2000a).
- Epidermal growth factor, and its human homologue urogastrone are secreted by the gut-associated salivary and Brunner's glands.
- Recombinant EGF/URO is a powerful stimulator of cell proliferation and differentiation in the rodent and neonatal human intestine (Wright et al. 1990). Ulceration of the epithelium anywhere in the human gastrointestinal tract induces the development of a novel cell lineage from gastrointestinal stem cells. This lineage initially appears as a bud from the base of intestinal crypts, adjacent to the ulcer, and grows locally as a tubule, ramifying to form a new small gland, and ultimately emerges onto the mucosal surface.
- the lineage produces neutral mucin, shows a unique lectin-binding profile and immunophenotype, is nonproliferative, and contains and secretes abundant immunoreactive EGF/URO. It has been proposed that all gastrointestinal stem cells can produce this cell lineage after mucosal ulceration, secreting EGF/URO to stimulate cell proliferation, regeneration and ulcer healing. This cell lineage is very commonly associated with gastrointestinal mucosal ulceration, and a principal in vivo role for EGF/URO is to stimulate ulcer healing throughout the gut through induction of this cell lineage in the adjacent mucosa (Wright et al. 1990). The relevance of G-CSF to IBD was discussed above (see Comparison 2).
- Thl T-helper type 1 cytokines IL-18 may play a key pathogenetic role in Thl -mediated disorders, such as CD. Regulation and expression of IL-18 appears to differ between CD and UC, and serum IL-18 may be a useful clinical marker for CD (Furuya et al. 2002). Macrophages, and the macrophage-derived IL-18, play a pivotal role in the establishment of TNBS-induced colitis in mice (Kanai et al. 2001), highlighting the potential use of therapy directed against IL-18 in the treatment of patients with CD.
- EGF EGF, G-CSF, IL-18 or other cytokines will not be able to correctly classify samples with high success rate, but when used in combination with other cytokines in the 6-cytokine classifier, the correct classification rate is considerably improved.
- the SDs for each analyte for all UC patients were summed, and analytes were sorted according to the sums, with the lowest sums shown on the left and the highest sums shown on the right.
- the sample IDs are shown on the left, with the top 20 rows representing UC patients, and the rest of the rows representing normal controls.
- the analyte abbreviations are shown at the bottom of the figure.
- VEGF vascular endothelial growth factor
- P1GF placenta growth factor
- the serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7. J Clin Immunol 17:282-92 Wright NA, Pike C, Elia G (1990) Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gasfrointestinal stem cells.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47424803P | 2003-05-30 | 2003-05-30 | |
PCT/US2004/017024 WO2005009339A2 (en) | 2003-05-30 | 2004-06-01 | Inflammatory bowel diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1667669A2 true EP1667669A2 (de) | 2006-06-14 |
Family
ID=34102624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04776179A Withdrawn EP1667669A2 (de) | 2003-05-30 | 2004-06-01 | Entzündliche darmerkrankungen |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1667669A2 (de) |
WO (1) | WO2005009339A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2619735C (en) | 2005-08-31 | 2014-05-27 | Ith Immune Therapy Holdings Ab | Treatment of inflammatory bowel disease |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
EA201000131A1 (ru) * | 2007-08-02 | 2010-08-30 | АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ | Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника |
CN103649336A (zh) | 2011-05-10 | 2014-03-19 | 雀巢产品技术援助有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
KR20160005044A (ko) * | 2013-05-17 | 2016-01-13 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
EP3094973B1 (de) | 2013-11-07 | 2020-07-29 | Diagnodus Limited | Biomarker |
CA2939246A1 (en) | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
CA3064529C (en) * | 2017-05-31 | 2021-12-14 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in crohn's disease patients |
-
2004
- 2004-06-01 WO PCT/US2004/017024 patent/WO2005009339A2/en active Application Filing
- 2004-06-01 EP EP04776179A patent/EP1667669A2/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2005009339A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005009339A3 (en) | 2006-05-18 |
WO2005009339A2 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alex et al. | Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis | |
JP2020098213A (ja) | 個別治療管理のための疾患活動性プロファイリングの方法 | |
Muls et al. | IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy | |
EP2904405B1 (de) | Verfahren zur vorhersage und überwachung von mukosale heilung | |
EP1667669A2 (de) | Entzündliche darmerkrankungen | |
Li et al. | Identification of novel population-specific cell subsets in Chinese ulcerative colitis patients using single-cell RNA sequencing | |
EP2996717A2 (de) | Unterschiedliche wirkungen von ifn-gamma und il-17 auf tl1a-modulierte entzündungen und fibrose | |
Lu et al. | The correlation of serums CCL11, CCL17, CCL26, and CCL27 and disease severity in patients with urticaria | |
Shieh et al. | KLF5 protects the intestinal epithelium against Th17 immune response in a murine colitis model | |
Chen et al. | Multiplex immunoassays reveal increased serum cytokines and chemokines associated with the subtypes of achalasia | |
US9835632B2 (en) | Biomarker panel for assessment of mucosal healing | |
Peluso et al. | Systems analysis of innate and adaptive immunity in Long COVID | |
Cilliers et al. | Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response | |
US20240002520A1 (en) | Treatment of castleman disease | |
Wintjens et al. | OP002 Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s disease cohort shows a quiescent disease course for a substantial proportion of the population | |
US20170219605A1 (en) | Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis | |
JP2019190976A (ja) | スティル病と敗血症との鑑別用バイオマーカー | |
Herman et al. | Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn’s disease? | |
Li et al. | Serum cytokine modulation after Staphylococcus hyicus infection in BALB/c mice | |
associated NMOSD | Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder | |
KrawiecΕ et al. | Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease | |
Toussirot et al. | POS0440 INCREASED FREQUENCY OF ACTIVATED MAIT CELLS EXPRESSING THE GUT HOMING RECEPTOR CCR9 IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | |
Jha et al. | Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis | |
Kuk et al. | IBD Basic Science | |
US20110200600A1 (en) | Diagnosis and prognosis of immune disorders using stat4 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/52 20060101ALI20060620BHEP Ipc: A61B 5/00 20060101AFI20060620BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PATHWAY DIAGNOSTICS CORPORATION, INC. |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
DAX | Request for extension of the european patent (deleted) | ||
17P | Request for examination filed |
Effective date: 20061117 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KINGSMORE, STEPHEN, F. Inventor name: PATEL, DHAVALKUMAR, D. Inventor name: KOTLER, GREGORY Inventor name: LEJNINE, SERGUEI Inventor name: TCHERNEV, VELIZAR, T. Inventor name: SATYARAJ, EBENEZER |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20080901 |